<DOC>
	<DOCNO>NCT01725594</DOCNO>
	<brief_summary>This two-part Phase 1 placebo-controlled , double-blind , randomized single multiple ascend dose study . In Part A , CAT-2003 administer single dose ; two dos ( 1000 2000 mg ) , subject return second dose CAT-2003 placebo high fat meal . In Part B , CAT-2003 administer 14 consecutive day .</brief_summary>
	<brief_title>A Single Multiple Ascending Dose Study Assess Safety , Pharmacokinetics Pharmacodynamics CAT-2003</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Major Provision write informed consent prior studyspecific procedure ; Good health determine medical history , physical examination , vital sign , ECG , clinical laboratory measurement ; Satisfies one following : 1 . Females childbearing potential : nonpregnant nonlactating ; surgically sterile postmenopausal 2 year least 1 year follicle stimulate hormone assessment ( FSH ) great equal 40 IU/L ; OR 2 . Males : surgically sterile , abstinent , subject partner utilize acceptable contraceptive method 3 month last study dose ; Major Clinically significant disease require physician 's care and/or would interfere study evaluation Clinically significant electrocardiogram ( ECG ) abnormalities laboratory result assess investigator , QTcF &gt; 450 ; Use investigational drug participation investigational study within 30 day prior screen 5 halflives study agent , whichever longer ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>